About Us
Our Team
Leadership
Noah Ullman
Co-Founder & Co-CEO
Noah received his degree in business from Montana State University and has over a decade of experience in business development and strategic partnerships. His technical background includes machine learning and data science, pre-clinical drug discovery, healthcare economics, biotechnology R&D, life-science asset valuation, and healthcare data storage and analytics. Noah has worked with industry leaders in pharmaceuticals, clinical operations, digital health, AI-drug discovery, and patient advocacy. His unique skill set and insight into pharmaceutical and health care value chains makes him to an exceptional asset to our leadership team. Business aside, you can find him out enjoying New Hampshire's picturesque yet often frigid surf.
Trebor R. Lawton
Co-Founder & Co-CEO
Trebor is responsible for developing and delivering on strategic efforts in connection with Abyssinia’s R&D and commercialization goals. He has a demonstrated history in organizing the business and scientific components of research operations. After graduating with a degree in cellular and molecular biology from Connecticut College, he designed and executed a publicly funded study to detect vector-borne disease biomarkers in patient samples collected at a state-wide level in Maine. His experience expands into the wet lab where he has been involved in developing monoclonal antibodies to various fungal targets with Aliquot and Niche Diagnostics. Outside of work, Trebor leads an active lifestyle.
Dr. Robert Lawton PhD
Founding Scientist
Publishing under Trebor L. Lawton or TL Lawton, Robert is the founding scientist of Abyssinia Biologics and an immunologist specializing in immunogen design and antibody development. After his undergraduate and master’s studies in microbiology at Purdue University and medicine at Dartmouth University, he received his PhD in Immunology under the guidance of Dr. Jonathan Howard in the Immunology Department run by César Milstein at the University of Cambridge. After post-doctoral training with Ellis Reinherz at the Dana Farber Cancer Institute studying T-cell responses to HIV and with Jack Strominger at Harvard Medical School, he returned to Maine where his roots run nearly as deep as the granite that anchors her pointed firs. From 1991-2001 he served as Director of the Laboratory of Immunobiology at IDEXX Laboratories in Westbrook, Maine developing monoclonal reagents and assays for Veterinary diagnostics. For the last 20 years, he has been in the human biotechnology sector as founder and director of New England Rare Reagents, Niche Diagnostics, Aliquot, LLC and most recently, Abyssinia Biologics.
Additional Team Members & Advisors
Frederic Godderis
Strategy & Operations
Eric Yuen MD
Clinical Development
Saira Ramasastry
Corporate Strategy
Mark Matejevic
Translational Science
Michael Papile
Corporate Finance
Erica Pascal, PhD
Intellectual Property
Paul Treacy, PhD
CMC
Enchi Liu, PhD
Translational Science & Development Leadership
Guriq Basi, PhD
Antibody Design & Optimization
Brian Rogers, PhD
Toxicology
Raj Dua
CMC
Keith Jansen
Business Strategy
